How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AT

NASDAQ:ATXS
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AT

Astria Therapeutics IncNASDAQ ATXS Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ATXS undervalued compared to its fair value?

The fair value of ATXS stock is hidden USD. Relative to the market price of 11.66 USD Astria Therapeutics Inc is hidden.

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The compan...[More about valuation]

Astria Therapeutics Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.646 $B

Price:

11.66 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.861

FINANCIALS

Astria Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.034 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.031 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.25 B
0.24 B

Financial Position Analysis

Assets

0.25 B
Current Assets
0.25 B
Total non-current assets
0.0037 B

Total current liabilities
0.012 B
Total non-current liabilities

Cash Flow Statement

-0.03 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.03 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Astria Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Astria Rating

Is ATXS attractive for investment based on fundamental analysis?

ATXS stock rating is hidden. Astria Therapeutics is a hidden by Eyestock methodology.

Get ATXS Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ATXS analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ATXS to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Astria Therapeutics Inc dividends

ATXS dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ATXS stock

About the company Astria Therapeutics Inc

Market cap $B

0.646

Dividend yield

Shares outstanding

17.0514 B

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2015-06-25. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.

ATXS profile

  • Ticker

    ATXS

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    25 June 2015

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    29

  • City

    Boston

  • Address

    75 State Street, Suite 1400

  • Cusip

    04635X102

Frequently Asked Questions

What sector does Astria operate in?

Astria operates in Healthсare sector

What is market cap of Astria?

Market cap of Astria is 0.646 USD as of 24 Jul 2024

What is market price of one ATXS stock?

Market price of one ATXS stock is 11.66 USD as of 24 Jul 2024

What is Astria revenue?

According to the recent report Astria revenue is —

What is Astria net income?

According to the recent report Astria net icnome is -31.41

What is Astria net income growh rate?

Net income growth rate of Astria is —